Novozymes Biopharma Invests in New cGMP Facility for Production of Bacillus-based Hyaluronic Acid

29-Apr-2009 - China

Novozymes Biopharma, part of Novozymes announced the construction of a new cGMP facility at the company's existing site in Tianjin, China that will enable its novel form of Bacillus-based Hyaluronic Acid (bHA), HyaCare, to be used within the bio-medical and pharmaceutical industries.

Sketch of New Facility China

With a significant investment of over DKK 300 million, this new facility will produce bHA products to pharmaceutical grade Q7, paving the way for use in medical devices and pharmaceutical applications.

"The strategic decision to build this new facility was based on a thorough market review and the increasing demand for bHA. Regulators are ever more cautious with regards to the safety of products and so a cGMP compliant facility is an essential part of our strategy in bringing bHA forward for use in medical device and pharmaceutical applications," comments Hans Ole Klingenberg, Director, Novozymes Biopharma. "China was an obvious choice as we already have a world-class manufacturing operation there with more than 20 years experience. This site will also facilitate expansion as business opportunities develop."

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances